Channing J Der

32PUBLICATIONS
275CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Oct 08, 2026
Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS -mutant Pancreatic and Lung Cancer.

|Apr 29, 2026
KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer.

|Jan 20, 2026
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.

Rachel A Burge, Ozgun Le Roux, Olesja Popow

|Nov 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

Szu-Aun Long, Haley Todd, Grace Goodhart

|Oct 24, 2025
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.

Mandana Kamgar, G Aaron Hobbes, Raven Davidson

|Sep 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer.

Priya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp

Pageof 6

Frequent Collaborators

15 joint publications

Clint A Stalnecker

14 joint publications

Adrienne D Cox

12 joint publications

Andrew Waters

11 joint publications

Kirsten L Bryant